Latest Akero Therapeutics News & Updates

See the latest news and media coverage for Akero. We track all announcements, press releases, and industry mentions in real time, all in one place.

Akero Therapeutics (Akero)

Clinical-stage biopharmaceutical company

akerotx.com

Headquarters: South San Francisco, United States
Founded year: 2017
Company type: Public company
Number of employees: 10–80

Last updated Today

Latest news about Akero Therapeutics (Akero)

In short: Akero was acquired by Novo Nordisk for up to $5.2 billion to advance efruxifermin for metabolic dysfunction-associated steatohepatitis.

Company announcements

June 5 Akero

Akero's efruxifermin shows consistent efficacy in MASH trials

New analyses from HARMONY and SYMMETRY trials published in Hepatology demonstrate antifibrotic and metabolic efficacy regardless of PNPLA3 genotype.

22 December 2025 Akero

Akero Therapeutics reflects on 2025 achievements

They showed cirrhosis reversal in Phase 2b trial, completed Phase 3 enrollment, and finalized Novo Nordisk acquisition. They anticipate 2026 progress.

9 December 2025 Akero

Akero Therapeutics completes acquisition by Novo Nordisk

This milestone advances efruxifermin for MASH treatment, complementing Novo Nordisk's metabolic disease portfolio.

7 November 2025 Akero

Akero Therapeutics shares new efruxifermin data at AASLD

They present posters and oral sessions on antifibrotic activity from SYMMETRY and HARMONY trials.

Media coverage

April 21 MSN

Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion

Under the terms of the deal, Novo Nordisk will initially pay $54 a share in cash, or $4.7 billion, upon closing. Akero shareholders will also...

April 8 Pharmaceutical Executive

Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics | PharmExec

Novo Nordisk acquires Akero Therapeutics to enhance its portfolio with efruxifermin, a promising treatment for metabolic dysfunction-associated steatohepatitis.

March 19 Kavout

What Drove Avoro Capital Advisors' Strategic Exit from Akero Therapeutics

Avoro Capital Advisors sold its entire stake in Akero Therapeutics for $187.81 million. This strategic exit followed Novo Nordisk's $5.2 billion acquisition of Akero. The...

20 November 2025 Morningstar

Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero ...

Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale...

Never miss news about Akero

Track Akero and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.